Back to search

Peptide record

TPDB16490

Antibacterial Hemolysis Toxicity standard
16 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB16490
Antibacterial Hemolysis Toxicity
Anti-infective peptides Toxicity and safety peptides
dbAMP Peptipedia PD_Hemolysis
standard
No
A 16-aa standard-residue multi-activity (Antibacterial, Hemolysis, and Toxicity) peptide sequence curated from dbAMP, Peptipedia, and PD_Hemolysis, with an available 3D structural model.
Sequence
CRWGRWLRKIRRWRPK
Physicochemical Analysis

Sequence-only estimates for a linear peptide with free termini, not experimentally measured molecular properties. Mass and formula exclude cyclization and disulfide formation. The optical estimates assume paired cysteines, 280 nm, 1 g/L and a 1 cm path. The N-end rule estimate is not a measured plasma half-life.

C103H165N39O17S1
ANDEQHMFSTYV
R
2253.75
12.71
8
0
5
+8
5.10
-1.794
48.75
Mammalian: 1.2 hour Yeast: >20 hour E.coli: >10 hour
16500
7.32
1
Residue Composition
number
0
A
6
R
0
N
0
D
1
C
0
E
0
Q
1
G
0
H
1
I
1
L
2
K
0
M
0
F
1
P
0
S
0
T
3
W
0
Y
0
V
Amino Acid Distribution
A: 0 R: 6 N: 0 D: 0 C: 1 E: 0 Q: 0 G: 1 H: 0 I: 1 L: 1 K: 2 M: 0 F: 0 P: 1 S: 0 T: 0 W: 3 Y: 0 V: 0
Chemical Descriptors
16 reviewed residue count
C103H165N39O17S1 sequence-only estimate (linear, free termini)
2253.75 sequence-only estimate (linear, free termini)
12.71 sequence-only estimate (linear, free termini)
+8 sequence-only estimate (linear, free termini)
5.10 sequence-only estimate (linear, free termini)
-1.794 sequence-only estimate (linear, free termini)
Evidence Records 5 records
Evidence 1 Activity

Activity

50% Hemolysis
Toxicity
12.5 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | 12.5 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
The effect of structural modification of antimicrobial peptides on their antimicrobial activity, hemolytic activity, and plasma stability. | J Pept Sci | 2021
Evidence 2 Activity

Activity

95% Hemolysis
Toxicity
100 µg/mL
Hemolytic Cytotoxic
95% Hemolysis | 100 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
The effect of structural modification of antimicrobial peptides on their antimicrobial activity, hemolytic activity, and plasma stability. | J Pept Sci | 2021
Evidence 3 Activity

Activity

50% Hemolysis
Toxicity
13.1 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | 13.1 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
The effect of structural modification of antimicrobial peptides on their antimicrobial activity, hemolytic activity, and plasma stability. | J Pept Sci | 2021
Evidence 4 Activity

Activity

95% Hemolysis
Toxicity
100 µg/mL
Hemolytic Cytotoxic
95% Hemolysis | 100 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Evidence 5 Hemolysis

Source & Reference

PD_Hemolysis
PD_Hemolysis